Scope of the Study
Tardive dyskinesia is a condition affecting the nervous system often long term use of some psychiatric drugs. It may appear as repetitive, jerking movements that occur in the face, neck and tongue. It can be very troubling for the patient. The long term use of medications called antipsychotics and some medications used for nausea can cause tardive dyskinesia. The one patient out of four who receive long term treatment with an antipsychotic will experience tardive dyskinesia. Elder people, females, diabetics and other mental illness are certain factors which increase the risk of tardive dyskinesia. There are many treatments available for tardive dyskinesia, but a response to the treatment depends on the patient.
The market study is being classified, by Application (Hospitals, Ambulatory Surgical Centers and Diagnostic Centers) and major geographies with country level break-up.
Teva Pharmaceutical Industries (Israel), Biogen (United States), Johnson and Johnson (United States), GlaxoSmithKline (United Kingdom), Neurocrine Biosciences (United States), Pfizer (United States), Novartis (Switzerland), Sanofi (France), AstraZeneca (United Kingdom) and Bayer AG (Germany) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Tardive Dyskinesia market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Tardive Dyskinesia market by Type, Application and Region.
On the basis of geography, the market of Tardive Dyskinesia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Dopamine-Depleting Medications will boost the Tardive Dyskinesia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Blood Tests will boost the Tardive Dyskinesia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of Psychiatric Patients
- Rising Number of Hospitals and Clinics
- Increasing Research and Development Activities
- Expensive Treatment Options Available In the Market
- Rising Use of Antipsychotic Drugs
- Growing Geriatric Population Worldwide
- Lack of Awareness among People
Recently, the United States Food and Drug Administration approved Ingrezza (Valbenazine) capsules to treat adults with tardive dyskinesia. This was the first drug approved by the FDA for this condition.
Key Target AudienceTardive Dyskinesia Treatment Providers, Emerging Companies, Research Institutes, Government Body & Associations and End-user
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase